126 related articles for article (PubMed ID: 37173152)
1. Predicting post-recurrence survival for patients with pancreatic cancer recurrence after primary resection: A Bi-institutional validated risk classification.
van Oosten AF; Daamen LA; Groot VP; Biesma NC; Habib JR; van Goor IWJM; Kinny-Köster B; Burkhart RA; Wolfgang CL; van Santvoort HC; He J; Molenaar IQ
Eur J Surg Oncol; 2023 Sep; 49(9):106910. PubMed ID: 37173152
[TBL] [Abstract][Full Text] [Related]
2. Isolated pulmonary recurrence after resection of pancreatic cancer: the effect of patient factors and treatment modalities on survival.
Groot VP; Blair AB; Gemenetzis G; Ding D; Burkhart RA; van Oosten AF; Molenaar IQ; Cameron JL; Weiss MJ; Yang SC; Wolfgang CL; He J
HPB (Oxford); 2019 Aug; 21(8):998-1008. PubMed ID: 30777697
[TBL] [Abstract][Full Text] [Related]
3. Predicting Long-term Disease-free Survival After Resection of Pancreatic Ductal Adenocarcinoma: A Nationwide Cohort Study.
van Goor IWJM; Schouten TJ; Verburg DN; Besselink MG; Bonsing BA; Bosscha K; Brosens LAA; Busch OR; Cirkel GA; van Dam RM; Festen S; Koerkamp BG; van der Harst E; de Hingh IHJT; Intven MPW; Kazemier G; Los M; Meijer GJ; de Meijer VE; Nieuwenhuijs VB; Roos D; Schreinemakers JMJ; Stommel MWJ; Verdonk RC; van Santvoort HC; Daamen LA; Molenaar IQ;
Ann Surg; 2024 Jan; 279(1):132-137. PubMed ID: 37450706
[TBL] [Abstract][Full Text] [Related]
4. Implications of the Pattern of Disease Recurrence on Survival Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma.
Groot VP; Gemenetzis G; Blair AB; Ding D; Javed AA; Burkhart RA; Yu J; Borel Rinkes IH; Molenaar IQ; Cameron JL; Fishman EK; Hruban RH; Weiss MJ; Wolfgang CL; He J
Ann Surg Oncol; 2018 Aug; 25(8):2475-2483. PubMed ID: 29948425
[TBL] [Abstract][Full Text] [Related]
5. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial.
Conroy T; Castan F; Lopez A; Turpin A; Ben Abdelghani M; Wei AC; Mitry E; Biagi JJ; Evesque L; Artru P; Lecomte T; Assenat E; Bauguion L; Ychou M; Bouché O; Monard L; Lambert A; Hammel P;
JAMA Oncol; 2022 Nov; 8(11):1571-1578. PubMed ID: 36048453
[TBL] [Abstract][Full Text] [Related]
6. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
[TBL] [Abstract][Full Text] [Related]
7. The investigation of the survival time after recurrence in patients with pancreatic ductal adenocarcinoma for individualization of adjuvant chemotherapy.
Yamada D; Eguchi H; Iwagami Y; Asaoka T; Noda T; Kawamoto K; Gotoh K; Kobayashi S; Mori M; Doki Y
Surg Today; 2018 Oct; 48(10):952-962. PubMed ID: 29770847
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.
Herman JM; Fan KY; Wild AT; Hacker-Prietz A; Wood LD; Blackford AL; Ellsworth S; Zheng L; Le DT; De Jesus-Acosta A; Hidalgo M; Donehower RC; Schulick RD; Edil BH; Choti MA; Hruban RH; Pawlik TM; Cameron JL; Laheru DA; Wolfgang CL
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):678-85. PubMed ID: 23773391
[TBL] [Abstract][Full Text] [Related]
9. Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer.
Macedo FI; Ryon E; Maithel SK; Lee RM; Kooby DA; Fields RC; Hawkins WG; Williams G; Maduekwe U; Kim HJ; Ahmad SA; Patel SH; Abbott DE; Schwartz P; Weber SM; Scoggins CR; Martin RCG; Dudeja V; Franceschi D; Livingstone AS; Merchant NB
Ann Surg; 2019 Sep; 270(3):400-413. PubMed ID: 31283563
[TBL] [Abstract][Full Text] [Related]
10. Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy.
Schmocker RK; Delitto D; Wright MJ; Ding D; Cameron JL; Lafaro KJ; Burns WR; Wolfgang CL; Burkhart RA; He J
J Am Coll Surg; 2021 Apr; 232(4):405-413. PubMed ID: 33338577
[TBL] [Abstract][Full Text] [Related]
11. Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study.
Nahm CB; Turchini J; Jamieson N; Moon E; Sioson L; Itchins M; Arena J; Colvin E; Howell VM; Pavlakis N; Clarke S; Samra JS; Gill AJ; Mittal A
Eur J Surg Oncol; 2019 Feb; 45(2):218-224. PubMed ID: 30348604
[TBL] [Abstract][Full Text] [Related]
12. The canary in the coal mine: the growth of patient-derived tumorgrafts in mice predicts clinical recurrence after surgical resection of pancreatic ductal adenocarcinoma.
Thomas RM; Truty MJ; Kim M; Kang Y; Zhang R; Chatterjee D; Katz MH; Fleming JB
Ann Surg Oncol; 2015; 22(6):1884-92. PubMed ID: 25404477
[TBL] [Abstract][Full Text] [Related]
13. Estimating Recurrence after Upfront Surgery in Patients with Resectable Pancreatic Ductal Adenocarcinoma by Using Pancreatic CT: Development and Validation of a Risk Score.
Kim DW; Lee SS; Kim SO; Kim JH; Kim HJ; Byun JH; Yoo C; Kim KP; Song KB; Kim SC
Radiology; 2020 Sep; 296(3):541-551. PubMed ID: 32662759
[TBL] [Abstract][Full Text] [Related]
14. Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma.
Groot VP; Rezaee N; Wu W; Cameron JL; Fishman EK; Hruban RH; Weiss MJ; Zheng L; Wolfgang CL; He J
Ann Surg; 2018 May; 267(5):936-945. PubMed ID: 28338509
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Survivors after Upfront Resection for Pancreatic Ductal Adenocarcinoma: An Actual 5-Year Analysis of Disease-Specific and Post-Recurrence Survival.
Belfiori G; Crippa S; Francesca A; Pagnanelli M; Tamburrino D; Gasparini G; Partelli S; Andreasi V; Rubini C; Zamboni G; Falconi M
Ann Surg Oncol; 2021 Dec; 28(13):8249-8260. PubMed ID: 34258720
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma in the Netherlands: A Nationwide Retrospective Analysis.
de Rooij T; Tol JA; van Eijck CH; Boerma D; Bonsing BA; Bosscha K; van Dam RM; Dijkgraaf MG; Gerhards MF; van Goor H; van der Harst E; de Hingh IH; Kazemier G; Klaase JM; Molenaar IQ; Patijn GA; van Santvoort HC; Scheepers JJ; van der Schelling GP; Sieders E; Busch OR; Besselink MG;
Ann Surg Oncol; 2016 Feb; 23(2):585-91. PubMed ID: 26508153
[TBL] [Abstract][Full Text] [Related]
17. [Surgical therapy of pancreatic cancer - 5 years survival].
Loveček M; Skalický P; Klos D; Neoral Č; Ehrmann J; Zapletalová J; Švébišová H; Yogeswara T; Ghothim M; Vrba R; Havlík R
Rozhl Chir; 2015 Nov; 94(11):470-6. PubMed ID: 26766155
[TBL] [Abstract][Full Text] [Related]
18. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant chemotherapy after surgery for pancreatic ductal adenocarcinoma: retrospective real-life data.
Chikhladze S; Lederer AK; Kousoulas L; Reinmuth M; Sick O; Fichtner-Feigl S; Wittel UA
World J Surg Oncol; 2019 Nov; 17(1):185. PubMed ID: 31706323
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the significance of adjuvant chemotherapy in patients with stage ⅠA pancreatic ductal adenocarcinoma.
Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Matsunaga Y; Shiihara M; Yamamoto M
Pancreatology; 2021 Apr; 21(3):581-588. PubMed ID: 33579600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
